seres therapeutics stock price target
Stock quote stock chart quotes analysis advice financials and news for share SERES THERAPEUTICS INC. Seres Therapeutics stock forecast analyst price target predictions based on 4 analysts offering 12-months price targets for MCRB in the last 3 months.
Mcrb Stock Price And Chart Nasdaq Mcrb Tradingview
MCRB stock quote history news and other vital information to help you with your stock trading and investing.
. MCRB updated stock price target summary. The company traded as high as 707 and last traded at. Get a real-time Seres Therapeutics Inc.
Based on 4 Wall Street analysts offering 12 month price targets for Seres Therapeutics in the last 3 months. NASDAQMCRB Get Rating s stock price shot up 81 during mid-day trading on Thursday. The forecasts range from a low of 900 to a high of.
The 7 analysts offering 12-month price forecasts for Seres Therapeutics Inc have a median target of 1200 with a high estimate of 2500 and a low estimate of 400. 13 2017 at 755 am. That Seres Therapeuticss share price could reach 900 by Sep 7 2023.
Based on short-term price targets offered by five analysts the average price target for Seres Therapeutics comes to 1420. The latest price target for. The Wall Street analyst predicted.
MCRB stock price quote with breaking news financials statistics charts and more. Seres Therapeutics started at outperform with 19 stock price target at Oppenheimer Oct. Get a real-time Seres Therapeutics Inc.
ET by Tomi Kilgore Seres Therapeutics stock drops 19 on clinical trial results. The current price of Seres Therapeutics is the price at. Youll get all this info in one place.
Seres Therapeutics Inc. The best long-term short-term Seres Therapeutics share price. MCRB Stock Price Prediction.
Seres Therapeutics Inc Price Forecast Insider Ratings Fundamentals Signals Current. Price target in 14 days. MCRB was reported by Piper Sandler on September 7 2022The analyst firm set a price target for 900 expecting MCRB to rise to.
The 9 analysts offering price forecasts for Seres Therapeutics have a median target of 2078 with a high estimate of 4600 and a low estimate of 700. Find the latest Seres Therapeutics Inc. Stock Price Target MCRB.
Seres Therapeutics Stock Forecast Invest in MCRB NASDAQMCRB. A The latest price target for Seres Therapeutics NASDAQ. Analyst ratings historical stock prices earnings estimates actuals.
Deutsche Boerse AG. The average price target is 1533 with a high. What is the target price for Seres Therapeutics MCRB stock.
The median estimate represents a. Seres Therapeutics Target Price Projection Seres Therapeutics current and average target prices are 693 and 2283 respectively. The average Seres Therapeutics stock price prediction forecasts a potential upside of.
The average Seres Therapeutics stock price prediction forecasts a potential upside of 3783 from the current MCRB share price of 653. MCRB was reported by Piper Sandler on.
Best Choice Seres Therapeutics Stock Update 1 Website Cung Cấp Thong Tin Cong Nghệ Mới Nhất Vn
Seres Therapeutics Biotech Reviews
Seres Therapeutics Inc Mcrb Stock Price Quote News Stock Analysis
Is Seres Therapeutics Still A Buy After Disappointing Ser 287 Topline Results
Seres Therapeutics Reports First Quarter 2021 Financial Results And Provides Business Updates Business Wire
Seres Therapeutics Reports Third Quarter Financial Results And Provides Business Update Business Wire
Why Seres Therapeutics Shares Are Popping Off Today Markets Insider
Nestle Bets 525m On Seres Therapeutics Microbiome Drug For Infectious Diseases Benzinga
Analysts Expect Seres Therapeutics Inc Nasdaq Mcrb Will Post Earnings Of 0 56 Per Share Defense World
Seres Therapeutics Mcrb Stock Price News Info The Motley Fool
Best Biotech Stocks Which Companies Have Growth Potential
Implied Xbi Analyst Target Price 190
Seres Therapeutics Inc Research Ratings Mcrb Barron S
Seres Therapeutics Mcrb Historical Forecast Data Trefis Trefis
Earnings Preview Seres Therapeutics Seres Therapeutics Nasdaq Mcrb Benzinga
Our Programs Seres Therapeutics
Seres Therapeutics Inc Mcrb Stock Price Quote News Stock Analysis
Seres Surges 611 After Colon Therapy Meets Goal In Study Bloomberg